Orion Therapeutics, Inc.

The recent success of mRNA vaccines in the fight against COVID-19 has placed RNA-based pharmaceutical strategies center-stage in the biotech community.

This medical milestone marks an inflection point in human history that will revolutionize the pharmaceutical industry from top-to-bottom, providing cures for the incurable and improving the overall quality of life for patients across the globe.

However, the primary challenge hindering commercialization of these RNA drugs is the issue of DELIVERY.

There are nearly 1500 nucleic acid-based drugs (RNA or DNA) currently in preclinical development for a wide range of disease applications including cancer, cardiovascular disease, HIV, Alzheimer's, and certain forms of blindness to name a few.